Charlotte Magdelaine–Beuzelin

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens et al. · Gastroenterology · 2008 · 497 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

Konstantinos Κarmiris, Gilles Paintaud, Maja Noman et al. · Gastroenterology · 2009 · 478 citations · Full text

Life Sciences, Clinical Sciences, Immunology +16

Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

David Ternant, Alexandre Aubourg, Charlotte Magdelaine–Beuzelin et al. · Therapeutic Drug Monitoring · 2008 · 181 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

Charlotte Magdelaine–Beuzelin, Séverine Vermeire, Margaret Goodall et al. · Pharmacogenetics and Genomics · 2009 · 76 citations

Life Sciences, Genetics, Immunology +17

Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis

Denis Mulleman, D. Chu Miow Lin, Émilie Ducourau et al. · Therapeutic Drug Monitoring · 2010 · 66 citations

Medicine, Pharmacology, Pharmacotherapy +17